RxDoctor Payments Data

Tina Lee, MD

Family Medicine · Columbus, OHNPI 1982924619

Payments from drug & device makers

$2,352in general payments, 2019–2025

Across 100 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$734
  • Novo Nordisk$445
  • AbbVie$177
  • Lilly USA, LLC$137
  • Boston Scientific$77
  • Boehringer Ingelheim$64
  • plus $718 from 25 others

What the payments were for

  • Food & beverage$2,352100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,352 in reported general payments places this provider in the 75th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$35,502
Medicare patients
84
Services billed
378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide36$64,895
EliquisApixaban15$22,689
OzempicSemaglutide21$20,666
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,330
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$8,927
Duloxetine Hcl15$1,933
Atorvastatin Calcium210$1,784
Rosuvastatin Calcium130$1,757
Nebivolol Hcl14$1,664
Levothyroxine Sodium142$1,342
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,102
Ipratropium Bromide29$1,059
Gabapentin42$1,022
Metoprolol Succinate80$965
Losartan Potassium88$895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$137$64,89536 claims
PfizerEliquis$48$22,68915 claims
Novo NordiskOzempic$445$20,66621 claims
GSKTrelegy Ellipta$21$10,33014 claims
AstraZenecaBreztri Aerosphere$734$8,92712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →